We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Clinical features and outcomes of four atypical hemolytic uremic syndrome cases at a single institution in Miyazaki Prefecture from 2015 to 2019.
- Authors
Kawano, Noriaki; Abe, Tomohiro; Ikeda, Naoko; Nagahiro, Yuri; Kawano, Sayaka; Tochigi, Taro; Nakaike, Takashi; Yamashita, Kiyoshi; Kubo, Keisuke; Yamanaka, Atsushi; Terasaka, Sohshi; Marutsuka, Kousuke; Mashiba, Koichi; Kikuchi, Ikuo; Shimoda, Kazuya; Matsumoto, Masanori; Ochiai, Hidenobu
- Abstract
Background: Although atypical hemolytic uremic syndrome (aHUS) is a life-threatening clinical entity that was characterized by thrombotic microangiopathy (TMA) with the activation of the complement system and the efficient treatment of eculizumab, the clinical features of aHUS have been unclear because of the rare incidence. Case presentation: We retrospectively analyzed 4 aHUS cases at a single institution during 2015–2019. Here, we presented 4 aHUS cases with renal transplantation (one case), influenza/acute interstitial pneumonia/disseminated intravascular coagulation (two cases), and severe fever with thrombocytopenia syndrome (one case), respectively. Initial clinical symptoms were microangiopathic hemolytic anemia (four cases), renal dysfunction (four cases), thrombocytopenia (four cases), and pulmonary hemorrhage (three cases) consisted with TMA features. Subsequent further examinations ruled out thrombotic thrombocytopenic purpura, Shiga toxin-producing E.coli-induced hemolytic uremic syndrome, and secondary TMA. Taken these findings together, we made the clinical diagnosis of aHUS. Furthermore, all cases also presented the high levels of plasma soluble C5b-9 (871.1 ng/ml, 1144.3 ng/ml, 929.2 ng/ml, and 337.5 ng/ml), suggesting persistent activation of complementary system. Regarding the treatment, plasma exchange (PE) (four cases) and eculizumab (two cases) therapy were administered for aHUS cases. Consequently, case 2 and case 4 were still alive with 768 days and 235 days, respectively. The other two cases were dead at 34 days and 13 days, respectively. Finally, although the previous reported genetic pathogenetic mutations were not detected in our cases, multiple genetic variants of complement factors were detected as CFH (H402Y, E936D), and THBD (A473V) in case 1, CFH (V62I, H402Y, V837I) in case 2, and CFH (H402Y, E 936D) and THBD (A473V) in case 3, CFH (V62I, H402Y, E936D) and THBD (473V) in case 4, respectively. Conclusions: Because of still high mortality in our study, an urgent diagnosis of aHUS and subsequent immediate treatment including PE and eculizumab should be essential in clinical practice. Furthermore, the multiple genetic variants and the triggers may be related to one of the pathogenesis of aHUS. Thus, we assume that such a case-oriented study would be highly useful to the physicians who directly care for aHUS cases in clinical practice.
- Subjects
JAPAN; INFLUENZA complications; HEMOLYTIC-uremic syndrome diagnosis; HEMOLYTIC-uremic syndrome treatment; PNEUMONIA; DISSEMINATED intravascular coagulation; FEVER; COMPLEMENT (Immunology); PREDNISOLONE; GENETIC mutation; PLASMA exchange (Therapeutics); KIDNEY transplantation; MONOCLONAL antibodies; TREATMENT effectiveness; HEMOLYTIC-uremic syndrome; THROMBOCYTOPENIA; DISEASE risk factors; SYMPTOMS; DISEASE complications
- Publication
Renal Replacement Therapy, 2022, Vol 8, Issue 1, p1
- ISSN
2059-1381
- Publication type
Article
- DOI
10.1186/s41100-022-00396-6